Resuscitative Endovascular Balloon Occlusion of the Aorta in Non-traumatic Out of Hospital Cardiac Arrest
Launched by ST. OLAVS HOSPITAL · Oct 15, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for patients who experience a sudden cardiac arrest outside of a hospital. Cardiac arrest is a serious condition where the heart stops beating, and immediate medical help is crucial. The goal of this trial is to see if using REBOA alongside standard life-saving measures, known as Advanced Cardiovascular Life Support (ACLS), can improve outcomes for these patients. REBOA works by temporarily blocking blood flow in a major artery to help redirect blood to vital organs during cardiopulmonary resuscitation (CPR), which may increase the chances of heart function returning.
To be eligible for this trial, participants must have experienced a non-traumatic cardiac arrest (not due to injury) and must have received basic or advanced life support within 10 minutes of the arrest. Patients who are pregnant, have certain medical conditions, or who have experienced traumatic cardiac arrests will not be included. If someone is chosen to participate, they can expect to receive the standard life-saving treatments along with the experimental REBOA procedure. This research could lead to better resuscitation methods in the future if the results show that REBOA is beneficial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • out-of-hospital cardiac arrest
- • non-traumatic cardiac arrest
- • less than 10 minutes from debut of arrest to start of basic or advanced cardiac life support
- • advanced cardiac life support is established and can be continued
- Exclusion Criteria:
- • traumatic cardiac arrest, including strangulation, electrocution and patients rescued from avalanches
- • accidental hypothermia with temperature \< 32 0C
- • suspected cerebral hemorrhage as etiology of the arrest
- • suspected non-traumatic hemorrhage as etiology of the arrest
- • pregnancy, obvious or suspected
- • patient included to the study site's E-CPR protocol
- • other factors as decided by the treatment team (environmental factors, safety factors and others)
About St. Olavs Hospital
St. Olavs Hospital is a leading healthcare institution located in Trondheim, Norway, renowned for its commitment to advancing medical research and improving patient care. As a key clinical trial sponsor, the hospital is dedicated to conducting innovative research across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With state-of-the-art facilities and a patient-centric approach, St. Olavs Hospital aims to enhance clinical outcomes and contribute to the global body of medical knowledge through rigorous and ethically conducted clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Stavanger, , Norway
Drammen, , Norway
Trondheim, , Norway
Aarhus, , Denmark
Billund, , Denmark
Ringsted, , Denmark
Skive, , Denmark
Bologna, , Italy
Oslo, , Norway
Oslo, , Norway
Patients applied
Trial Officials
Rune Wiseth, MD, PhD
Study Director
St Olav&amp;#39;s Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials